Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $3,809.0K | ($9,348.0K) | ($45.2M) | ($113.0M) | ($46.0M) | ($688.6M) | ($908.9M) | ($1,512.5M) | ($1,613.6M) | ($1,965.7M) | ($1,738.7M) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, BeiGene, Ltd.'s last 12-month Free Cash Flow is ($1,009.2M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, BeiGene, Ltd.'s Free Cash Flow growth was (45.5%). The average annual Free Cash Flow growth rates for BeiGene, Ltd. have been (0.7%) over the past three years, 2.7% over the past five years.
Over the last year, BeiGene, Ltd.'s Free Cash Flow growth was (45.5%), which is lower than industry growth of (0.1%). It indicates that BeiGene, Ltd.'s Free Cash Flow growth is Bad.